Skip to main content
OpenTrials
Completed

NCT Number: NCT07213115

Epidemiology and Treatment of Gastric Cancer

According to recent statistics, the incidence and mortality from gastric cancer are both worldwide in fifth place in terms of ranking. Gastric cancer is more common in males than in females. This difference in the incidence between males and females is likely due to the difference in exposure to some risk factors like Helicobacter pylori infection, family history of gastric cancer, dietary habits, smoking and alcohol. However these factors do not completely explain the different characteristics of gastric cancer between the sexes. Some studies have concluded that exposure to estrogen could reduce the risk of gastric cancer.

There is a lack of current population based and real world data on sex and age differences in gastric cancer care. Analyses of sex differences are primarily originate from Asia or focusing on older cohorts. In the Netherlands, Kalff et al. conducted a study with patients with gastric adenocarcinoma (n=2 072) registered in the Dutch Upper GI Cancer Audit between 2011 and 2016. In this study, patients without metastatic gastric cancer and with an elective surgery were included.

To close this sex and age data gap for patients including those with UICC IV stage and without surgery, the aim of our study was to analyze the sex and age differences in clinicopathological features and staging in gastric adenocarcinoma with cancer registry data from the Federal State of Brandenburg from 2000 to 2020.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • gastric adenocarcinomas (ICD-10-GM: C16.0 -C16.9)

Exclusion criteria

  • missing age or sex

Treatment and study plan

Gastrectomy+ chemotherapy

Procedure

Primary outcomes

  1. Overall survival

    Time frame: 5 year, 10 year

    Survival time after date of cancer diagnosis

Other outcomes

  1. sex differences

    Time frame: 5 year, 10 year

    Sex differences in epidemiology, Clinicopathological Characteristics, treatment, survival

Sponsors and collaborators

Lead sponsor

Medizinische Hochschule Brandenburg Theodor Fontane

Other

Collaborators

  • Margarete-Ammon-Stiftung

Registry information

Official study title

Epidemiology and Treatment of Gastric Cancer in the Federal State of Brandenburg From 2000 to 2020. An Analysis Using Data From the Clinical Cancer Registry for Brandenburg and Berlin.

Important dates

Study start
2000
Primary completion
2020
Study completion
2020
First posted
Oct 8, 2025
Registry last updated
Oct 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.